# OnCo record charm-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/charm-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "charm-therapeutics" ;
  schema:name "CHARM Therapeutics"@en ;
  schema:alternateName "Charm Therapeutics"@en, "CHARM Therapeutics Ltd"@en ;
  schema:description "CHARM Therapeutics is a London and Cambridge company using an AI protein-modelling tool to design medicines. Its first drug, CHM-029, is a menin inhibitor for acute myeloid leukaemia, built to keep working when the leukaemia becomes resistant to the first menin inhibitors."@en ;
  schema:url <https://onco.cc/companies/charm-therapeutics/>, <https://charmtx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://charmtx.com/>, <https://charmtx.com/charm-therapeutics-raises-80-million-in-series-b-financing-to-advance-development-of-best-in-class-menin-inhibitor-for-aml/>, <https://charmtx.com/charm-therapeutics-announces-first-patient-dosed-and-first-cohort-fully-enrolled-in-its-phase-i-ii-clinical-trial-of-chm-029-for-aml/>, <https://clinicaltrials.gov/study/NCT07751991> ;
  schema:addressCountry "GB" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-npm1-kmt2a/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/ai-computation/> ;
  onco:technologies <https://onco.cc/technologies/menin-inhibitors/>, <https://onco.cc/technologies/ai-drug-design/> ;
  onco:targets <https://onco.cc/targets/menin/>, <https://onco.cc/targets/kmt2a/>, <https://onco.cc/targets/npm1/>, <https://onco.cc/targets/nup98/> .